Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes

S. Sodin-Semrl, A. Spagnolo, B. Barbaro, J. Varga, Stefano Fiore*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Excessive production of interleukin-6 (IL-6) and metalloproteinases (MMPs) has been implicated in the pathogenesis of rheumatoid arthritis. Lipoxin A 4 (LXA4) and transforming growth factor β2 (TGF-β2) have potential anti-inflammatory activities; these two mediators were tested to determine how they affect IL-1β-dependent release of IL-6 and MMPs in human fibroblast-like synoviocytes. The results revealed dramatic differences between the mediators: TGF-β2 acted synergistically with IL-1β to stimulate IL-6 protein levels, whereas LXA4 inhibited IL-6 expression in a dose- and time-dependent manner. Inhibition, by LXA 4 was abrogated when cells were pre-incubated with antibody against the ALXR (Lipoxin A4 Receptor) TGF-β2 by itself had no significant effect on IL-6 or MMP levels. LXA4, at nanomolar concentrations, altered the MMP-1 and MMP-3 expression levels of IL-1β and TGF-1β stimulated fibroblast-like synoviocytes. Furthermore, IL-1β and TGF-β2 up-regulated ALXR mRNA. These results demonstrate, for the first time, that ALXR mediate the effects of LXA4 on inflammatory responses after stimulation of fibroblast-like synoviocytes with IL-1β plus TGF-β2. These activities might constitute an important mechanism by which LXA4 regulates synovial fibroblast activation.

Original languageEnglish (US)
Pages (from-to)15-25
Number of pages11
JournalInternational journal of immunopathology and pharmacology
Issue number1
StatePublished - 2004


  • Cytokines
  • Human
  • Inflammation
  • Lipid mediators

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes'. Together they form a unique fingerprint.

Cite this